Abstract: Engineering human tissues to enhance, replace or simulate physiological function has enormous potential to signifi cantly impact human healthcare. A fundamental feature of human tissue is a vascular supply. The creation of a living dynamic circulation has proved to be a signifi cant challenge. The past decade has brought several new approaches to create a vascular supply for three-dimensional human tissues for both in vitro and in vivo applications. However, future challenges remain, and new innovation in the areas of cell sourcing, the extracellular matrix, and controlling the immune response will be required to fully harness the potential of tissue engineering.
Introduction
The fi eld of tissue engineering is broad, and includes both the creation of new organs for those damaged by disease or trauma as well as three-dimensional (3D) in vitro models that can better replicate in vivo biology compared to two-dimensional (2D) monolayer culture (Griffi th and Swartz, 2006) . Regarding organ replacement, the fi eld, in general, has woefully underperformed since the initial excitement nearly 15 years ago when a scaffold resembling a human ear appeared on the dorsal surface of a mouse (Cao et al. , 1997) . Early laboratory successes at creating artifi cial skin struggled in the clinical and commercial sectors. While artifi cial skin is a US Food and Drug Administration (FDA) -approved medical device, cartilage is the only other engineered artifi cial tissue that has reached this lofty status. The underlying reasons for the lengthy delay in developing successful replacement tissues are many, but can generally be captured in the accepted paradigm: (1) a cell source is expanded in vitro , (2) the cells are seeded onto a scaffold, which supplies support and structure, and (3) the engineered tissue is introduced to the host to restore function. This paradigm requires a cell source(s) that is compatible with the host, and that, once implanted, requires removal of waste products and delivery of nutrients at rates that are compatible with tissue survival. The transport of nutrients and waste products in thin tissues (< 2 mm, e.g. artifi cial skin) can occur by simple diffusion (Brownian motion), at least initially, until full integration is achieved. However, thicker tissues will require convection as the primary mechanism of transport to enhance nutrient and waste exchange. A primary challenge for the fi eld of tissue engineering is to create a thick (≥ 1 cm) metabolically active 'tissue' that can survive implantation into a host. This will require rapid (< 24 hours) delivery of blood to the full thickness of the graft.
While 2D cell culture systems have long been the mainstay to understanding cell biology due to simplicity, reproducibility and affordability, these systems do not capture the rich cell-cell and cell-matrix interactions of the 3D in vivo tissue microenvironment that are so crucial to understanding tissue biology. The concept of creating in vitro 3D models of human organs can be traced back nearly four decades with the advent of 3D tumor spheroids to better represent growth and progression of cancer (Dalen and Burki, 1971; Sutherland et al. , 1971; Folkman and Hochberg, 1973) . These early systems, as well as the systems that followed, which attempted to mimic complex organs such as the heart (Bursac et al. , 1999; Papadaki et al. , 2001; Naito et al. , 2004; Radisic et al. , 2004) , lungs (Agarwal et al. , 2001; Choe et al. , 2003 Choe et al. , , 2006 Thompson et al. , 2006 Thompson et al. , , 2007 Malavia et al. , 2009) , and liver (Liu Tsang et al. , 2007; Domansky et al. , 2010) were relatively simple and limited in physical size by the lack of convective transport through a vessel network. In order to replicate the complex 3D arrangement of cells and extracellular matrix (ECM), new human microphysiological systems must be developed, and must include a vascular supply. The vasculature not only provides the necessary convective transport of nutrients and waste in 3D culture, it also couples and integrates the response of multiple organ systems.
This chapter will cover in detail the primary methods employed to vascularize engineered tissues, discuss some of the in vivo and in vitro applications of these vascularized tissues, and propose signifi cant challenges that must currently be overcome for these tissues to reach their full potential.
Strategies to vascularize engineered tissues

In-growth of native vessels
The most common approach to vascularize a tissue-engineered construct for implantation is to stimulate the in-growth of host vessels. The fi rst method includes degradable microcarriers, cellular transfection, or soft hydrogels as sources of pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF). For example, degradable microcarriers [e.g. poly-( D,L -lactide-coglycolide or poly(lactic-co-glycolic acid)] can be used to release angiogenic growth factors such as VEGF or basic fi broblast growth factor (bFGF) to stimulate in vivo angiogenesis (Cleland et al. , 2001; Perets et al. , 2003) . Alternatively, a mammalian cell can be transfected to overexpress an angiogenic cofactor and then be placed within the engineered tissue (Ajioka et al. , 2001) . Similarly, gelatin-based or alginate-based hydrogels have been preloaded with either bFGF or VEGF to stimulate angiogenesis in vivo (Lee et al. , 2000; Doi et al. , 2007; Silva and Mooney, 2007) .
The second approach involves the use of degradable polymer scaffolds that can provide bulk and porosity for an implantable device, and also encourage the ingrowth of vessels in vivo (Freed et al. , 1994; Loebsack et al. , 2001) . The polymeric scaffolds can also release pro-angiogenic growth factors ( Plate XIX , see color section between pp. 234 and 235). For example, degradable polylactic glycol scaffolds have been shown both to release VEGF and bFGF and to stimulate angiogenesis when implanted into a host (Perets et al. , 2003; Sun et al. , 2005; Ennett et al. , 2006) . The primary disadvantage of this approach is the reliance on diffusion to deliver nutrients and oxygen while waiting for the in-growth of new vessels from the host. This generally takes > 3 days, which may be too long to allow hypoxia-sensitive cells to survive in a truly thick tissue.
Microfabricated microfl uidic channels
Microfabrication technology has led to the creation of precise microchannels on non-biological substrates (e.g. silicon or polydimethyl siloxane) (Barenstein et al. , 2002; Shin et al. , 2004; Hsu et al. , 2010) , or within biological substrates such as collagen (Chrobak et al. , 2006; Price et al. , 2010; Zheng et al. , 2011) or fi brin (Miller et al. , 2012) , and a recent review has covered this topic in detail (Wong et al. , 2012) . These approaches offer several distinct advantages including control over the physical size (diameter, length) of the fl uidic channels, the branching characteristics (e.g. angles) of the channel network, and the essentially instant introduction of advection as a mechanism of transport. These advantages are offset by the lack of connection to the native circulation and pump, and the inability of the channels to respond to the dynamic metabolic needs of the tissue, even when 'endothelialized' (Myers et al. , 2012) . Nonetheless, the most recent example of this approach described a 3D network of 'vessels' cast from a sacrifi cial carbohydrate, surrounded by a cellularized fi brin matrix (colour Plate XX ) (Miller et al. , 2012) . The channels were lined by endothelial cells, and were shown to nourish nutrient-sensitive primary hepatocytes, and began to initiate new sprouts. The presence of endothelial cells clearly allows the potential for signifi cant remodeling of the network over time to meet changing metabolic needs, and so create a dynamic vascular network.
Spontaneous self-assembly (vasculogenesis) of capillaries from endothelial cells
Human endothelial cells (hECs) can be sourced from multiple tissues including, but not limited to, the umbilical vein (Dosne et al. , 1978; Gospodarowicz et al. , 1978) , umbilical cord blood (Fan et al. , 2003; Murga et al. , 2004) , peripheral adult blood (Ingram et al. , 2004; Fuchs et al. , 2006) and skin (Sherer et al. , 1980) , as well as human embryonic stem cells (Levenberg et al. , 2002) . When hEC are combined with a matrix such as collagen, fi brin, matrigel, or synthetic polymer, stromal cells (e.g. fi broblast, mesenchymal stem cell), and appropriate growth media, they spontaneously form a 3D network of human capillaries over the course of 3-7 days. The potential advantage of this strategy is that, if the vessel network is continuous following in vitro development, upon implantation, a minimal number of anastomostic sites with the host will result in rapid perfusion of the network and tissue. The vessel network could then remodel (pruning and extension) in response to the needs of the tissue. This technique has been used by numerous groups to 'prevascularize' an engineered tissue before implantation in an immune-compromised host (Levenberg et al. , 2005; Schechner et al. , 2000 Schechner et al. , , 2003 Melero-Martin et al. , 2007 Kang et al. , 2009; Chen et al. , 2009 Chen et al. , , 2010 Lin and Melero-Martin, 2011) . The hEC vessels anastomose with the host circulation within 1-7 days depending on the in vitro culture time and other factors such as hEC type and fi broblast concentration, demonstrating the potential for this approach (colour Plate XXI ). Our group has recently reported signifi cant clotting of blood following initial anastomosis using a window chamber and multispectral imaging (White et al. , 2012) highlighting the need to visualize fl ow dynamically and not rely solely on histological analysis of red blood cell-fi lled lumens. In this strategy, the vascular supply of the tissue is largely developed in vitro , thus overcoming the limitations of other strategies that rely on ingrowth of new vessels or the formation of new vessels following implantation.
Our group has recently used this technique to create a perfused vascular network of microvessels in a microfabricated device (Moya et al. , 2012 ). The vessels demonstrate physiological permeability (impermeable to 70 kDa fl uorescent dextran). Furthermore, fl ow includes a wide range of velocity (maximum 4000 μ m/s, mean 690 μ m/s) and shear (maximum 1000 1/s, mean 320 1/s) that encompass the physiological range which can be easily manipulated by controlling the pressure drop across the network.
Sprouting (angiogenesis) vessels from endothelial cell lined channels
An alternative method to create a functional vessel or vessel network in an in vitro tissue uses a combination of microfabrication technology and hECs.
Recently, it has been demonstrated that hECs lining fabricated channels directly within (Zheng et al. , 2012) or adjacent to (Song et al. , 2012) a collagen or fi brin (Yeon et al. , 2012) 
Microvessel fragments
An alternative strategy to prevascularize a tissue before implantation is to seed small isolated microvessel fragments into an appropriate extracellular matrix such as collagen (Hoying et al. , 1996; Shepherd et al. , 2004) . The microvessel segments demonstrate angiogenic potential following 5-7 days in culture. The microvessel fragments are isolated from the epididymal fat pads of rats, and, following implantation into an immune compromised mouse, the rat microvessels anastomose with the host vasculature. Of particular interest relative to other prevascularization strategies is the observation that this method results in a wider range of vessel types including arterioles, capillaries and venules, and so affords the possibility of a hierarchical vessel network more rapidly with perhaps less remodeling on the part of the host. This method has been used to augment vascularization of the myocardial wall following induced infarction in a mouse model (Shepherd et al. , 2007) .
In vivo conditioning
An intriguing method to vascularize an engineered tissue is to use the complex in vivo environment to condition or vascularize the engineer tissue. In this technique, the engineered tissue is placed inside the host, and essentially employs the host as the 'bioreactor' to develop the vascular supply in the engineered tissue, with the potential to then move the engineered tissue to a more permanent location. The most common method of in vivo conditioning is to create an arteriovenous (AV) loop ( colour Plate XXIII ) in which a vascular graft is surgically inserted as a bypass (or loop) from a small artery to a nearby venule (Mian et al. , 2000; Kneser et al. , 2006; Lokmic et al. , 2007; Manasseri et al. , 2007; Morritt et al. , 2007; Ren et al. , 2008; Dong et al. , 2010; Beier et al. , 2011; Boos et al. , 2013) . Within the space created by the loop, a tissue engineered construct is placed, and small vessels can sprout from the AV loop and enter the engineered tissue to provide nutrients and remove waste products. The potential drawback of this method is the time necessary for the in-growth of vessels, but a major advantage is the ability to remove the tissue once it is vascularized and have a convenient large vessel (from the AV loop) for surgical anastomosis at a permanent site. More recently, an alternative method of in vivo conditioning was presented in which tissue engineered cardiac tissue was placed initially on the highly vascular omentum of the host to become prevascularized, and then subsequently removed and placed within an infarcted region of the heart (Dvir et al. , 2009) . Although this approach to prevascularization led to functional tissue 4 weeks after transplantation from the omentum and into the heart, there remain several major disadvantages including: (1) the tissue dimensions remain in the order of 2-3 mm, (2) the technique requires two surgical procedures and (3) the in-growth of host vessels over a 7-day in vivo vascularization process, which is likely to be too long for thicker tissues > 1 cm.
Extracellular matrix
Any vascularized engineered tissue requires an ECM to support the vascular network. There are numerous models of the ECM that can generally be separated into naturally occurring and synthetic; they have recently been reviewed by Tian and George (2011) . The naturally occurring ECM mimics include: collagen, fi brin, starch, matrigel, silk fi brion and decelluarized ECM from the tissue of interest (e.g. cardiac tissue). The synthetic materials that have been successfully used to vascularize engineered tissues include functionalized polyethylene glycol and poly(lactic glycolic) acid. Although all of these materials can support vascularization, each has advantages and disadvantages. Broadly, the naturally occurring ECMs have inherent chemical and physical cues that support cell adhesion and vascular growth, and are easily degraded or remodeled by the host, but suffer from lot-to-lot variation, the potential for disease transmission, and are diffi cult to 'tune' mechanically or chemically to address more mechanistic questions. In contrast, the synthetic matrices are chemically defi ned, and so have little lot-to-lot variability and can be specially designed to address mechanistic questions; however, these matrices must be functionalized with binding sites (e.g. RGD sequence) for mammalian cells, and may be diffi cult for the host to degrade or remodel.
In vitro applications
Biological understanding of the tissue microenvironment
An important in vitro application of vascularizing engineered tissues is to simply enhance our general understanding of the dynamic and 3D human tissue microenvironment, as recently reviewed by Griffi th and . This application is a natural extension from the enormous understanding of cell biology (e.g. signal transduction, migration, proliferation) that simple 2D monolayer culture has provided over the past fi ve decades. In vivo , cells live in a 3D environment, and interact with a multitude of neighboring cells and extracellular matrix proteins, as well as the microcirculation. The interactions are non-linear, and include both chemical and mechanical components. Hence, our understanding of human biology will be dramatically improved as 3D models of the microenvironment are developed that include the microcirculation.
Drug discovery and chemical toxicity screening
While the actual cost of bringing a new drug to market is controversial, the magnitude remains enormous and signifi cantly impacts the cost of medication, and (Munos, 2009 ). This trend has been dubbed 'Eroom's Law' (Scannell et al. , 2012) , and the cost of bringing a single drug to market now exceeds one billion US dollars. In 2004, pharmaceutical companies spent approximately $37 billion in all phases of drug development. The two most costly steps (each ~ 25% of total) are preclinical testing of thousands of compounds to assess potential effi cacy and side effects, and phase III clinical trials in humans.
Only about 20% of drugs entering clinical trials make it to market, with 50% of drug candidates failing in expensive phase III trials due to lack of either safety or effi cacy (DiMasi et al. , 2003) . Hence, reducing the cost and improving the success rate depend strongly on our ability to both rapidly and cost-effectively screen compounds, and to better predict success in large-scale human trials. Chemotherapeutics to treat cancer, which typically have a shorter time to market, are particularly prone to failing in phase III trials (DiMasi and Grabowski, 2007) , and major cardiac side effects have become apparent only after approval and large-scale clinical use for several important drugs (Herman and Ferrans, 1998; Chu et al. , 2007) . Flat, 2D monocultures of tumor cells or normal cells do not begin to capture the complexity of the 3D tissue microenvironment. An ideal system for screening potential new drug candidates would be: 3D geometry; composed of tissue-specifi c cells, stromal cells, vasculature and matrix; affordable; rapid; reproducible; and suitable for high-throughput screening applications. In addition, a perfused vasculature would allow physiological nutrient and drug delivery.
The impact of creating in vitro 3D vascularized tissues that mimic the human tissue microenvironment is potentially paradigm-shifting for the fi eld of chemical toxicity screening. Humans are exposed to chemical toxins primarily through absorption through the skin, inhalation into the lungs, or ingestion. While acute toxicity to the initial organ of exposure can occur, toxins have the potential to be absorbed by the microcirculation and either damage the cardiovascular system directly or be delivered by convection to a distant site (e.g. liver, brain) of toxicity. Hence, the ability to screen chemical toxins to determine the permeability across human capillaries or direct toxicity to the microcirculation is of enormous importance in understanding the integrated effect of an individual toxin. Finally, the 'decision' by a tissue following insult (e.g. toxic chemical) to revitalize or undergo programmed death is poorly understood, yet is fundamental for our success in advancing human health, and must depend on a functional (i.e. perfused) capillary bed.
Personalized medicine
The response of humans to drugs is heterogeneous, and depends on numerous factors such as age, race, body mass and genotype. Some of these factors are well understood, while others are not. For example, it is well known that older people metabolize some classes of drugs slower. A growing interest in medicine is the concept that the specifi c drug and dosage can be tailored for an individual -'personalized medicine'. This potentially requires an inordinate amount of information (e.g. genotype for an individual), and could be laborious and cost prohibitive. However, the rapidly developing fi elds of high-throughput screening and stem cell technology provide hope that this approach may be used in the near future, at least for specifi c applications such as chemotherapy for cancer. A paradigm for personalized medicine already exists for some forms of cancer. Breast cancer is now widely recognized to have molecular subtypes based primarily on estrogen receptor and HER2 receptor status (Perou et al. , 2000) . Cells procured from a biopsy can be tested for their estrogen receptor and HER2 status and the results dictate therapy (Harbeck et al. , 2010) . More recently, it has been shown that endothelial growth factor receptor tyrosine kinase receptor inhibitors are more effective in lung cancers with endothelial growth factor receptor mutations (Mok et al. , 2010) . The advent of induced pluripotent stem cell technology allows cells such as skin fi broblasts, which are easily harvested from an individual, to be driven fi rst into a pluripotent stem cell, and then into essentially any cell type in the body. While differentiation protocols are still actively being developed and validated, this technology creates the possibility of creating in vitro disease models that are derived directly from a specifi c patient. In parallel, microfabrication technology (as described above) facilitates the creation of 3D organ mimics that are patient-specifi c.
In vivo applications
Whole organ replacement
Replacing a failing or diseased organ has long been the most obvious promise of tissue engineering. Examples include organs such as the kidney, liver and heart, all of which represent major sources of mortality in the USA, and for which there are active donor programs that fall far short of the demand (Sharing, 2012) . When these organs fail, a person's life is at stake. These organs are biologically complex, not only involving a multitude of different cell types with specialized functions, but also being physically large, cell dense, and with their viability and function dependent wholly on a vascular supply. Our ability to replace these complex organs with tissue engineered equivalents will undoubtedly depend on our ability to advance the fi eld of vascularized engineered tissues.
Organ enhancement or partial replacement
A more reachable goal of in vivo tissue engineering is the enhancement of an organ whose function is compromised by disease or aging. This might also be termed partial replacement. Early success stories of tissue engineering such as the 'skin equivalent' are just that -they replace a portion of the skin that has been -Teixeira et al. , 2011; Kock et al. , 2012) and small arteries (Dahl et al. , 2011; Quint et al. , 2011) . These approaches do not attempt to replace all of the cartilage or the entire arterial vessel tree; rather, these constructs attempt to replace specifi c parts of these organs that are diseased or failing. In this approach, the tissue engineered constructs can be smaller, less complex in their biological function, and so less dependent on a vascular supply. This approach to tissue engineering may extend lives, but the most obvious benefi t is the improvement in the quality of life.
Major barriers and future trends
11.5.1 Hierarchical vascular structure
Prevascularization strategies for implantable tissues, as well as vascularization of in vitro tissue models currently include only small vessels that most closely represent capillaries. Although some of the in vitro vessels may reach a diameter of 50-100 μ m Hsu et al. , 2012) , this does not include the rich hierarchical structure of the vascular system that is present in larger (in the order of centimeters) tissues that includes arterioles, capillaries and venules. In addition, the methods to currently create in vitro vascular networks tend to 'over-vascularize' tissue, and result in a density of capillaries and small vessels that far exceeds that present in vivo (White et al. , 2012) . This is likely due to the presence of exogenous growth factors such as VEGF, but other factors such as the ECM and oxygen tension may also contribute. Future in vitro vascularization strategies must plan for a hierarchical structure that more closely resembles the in vivo vascular structure to avoid clotting and extensive vessel remodeling, which could compromise tissue function.
Extracellular matrix
The extracellular matrix used by most in vitro vascularization strategies includes fi brin and/or collagen. Collagen is the most prevalent protein in the extracellular matrix, and fi brin is present in blood clots and so is present in healing wounds. While these proteins tend to stimulate angiogenesis, they do not replicate the extracellular matrix and so extensive remodeling is necessary to fully replicate the tissue of interest. More recently, decellularizing xenogeneic tissues offer an intriguing option to recover an ECM that more closely represents the proteins and other macromolecular content of native human tissue (Ott et al. , 2008; Petersen et al. , 2010) .
Cell source
A major hurdle in the creation of large (> 1 cm) complex tissues is producing an appropriate volume of cells. Cell dense and metabolically active tissues such as the myocardium or liver will require rapid vascularization, and these tissues contain > 10 × 10 6 cells/mL. Most primary adult human cells have severely limited ability to proliferate in vitro , and passaging cells invariably alters cell phenotype. Furthermore, to avoid an immune response upon implantation, xenogeneic or allogeneic sources of cells are not long-term solutions. The relatively recent ability to harvest, culture, expand and differentiate both embryonic and induced pluripotent human stem cells provides an enormous opportunity to create the vast number of specialized human cells for complex tissues. Both embryonic and induced pluripotent stem cells can be produced in very large quantities, and then differentiated into many, if not all, of the cell types in the human body. Further, use of the same induced pluripotent stem cell line as the source of specialized cells in tissue engineered constructs provides histocompatibility for in vitro human organ model systems, and the potential of personalized medicine that avoids immune rejection for in vivo implantation. Signifi cant challenges remain though, particularly in the differentiation step, which currently leads to cells that are neonatal in phenotype for essentially all specialized cell types (e.g. neuron, hepatocyte, cardiomyocyte) (Hedlund et al. , 2007; Navarro-Alvarez et al. , 2009; Gherghiceanu et al. , 2011; Grade et al. , 2012; Synnergren et al. , 2012) .
Tissue remodeling and immune response
Current technologies do not allow for the creation of a fully functional and vascularized tissue. The paradigm includes a tissue remodeling process once the engineered tissue is implanted, dictated by the host such that the remodeled tissue can meet the specifi c needs of the host. The remodeling process is initiated by the host and includes an immune response. Managing the immune response and remodeling process such that the implanted tissue becomes fully functional as opposed to degraded and potentially rendered completely dysfunctional remains a challenge. Challenges specifi c to the vascular supply include maintaining fl ow in the network of vessels such that remodeling of the vessel network can occur without compromising the delivery of nutrients and removal of waste products (e.g. carbon dioxide). We have previously shown that microvessel networks developed in vitro from endothelial cells tend to over-vascularize the tissue with too many and too small vessels.
Conclusion
Engineering complex 3D human tissues for in vitro or in vivo applications provides exciting opportunities to advance healthcare and thus quality of life. Early success included relatively thin and simple tissues (e.g. skin) that did not require a vascular supply; however, more complex and cell-dense tissues (e.g. liver) will require a vascular supply to meet the more demanding metabolic needs. Several strategies have been reported to vascularize engineered tissues that take advantage of recent advances in microfabrication, materials science, and stem cell technology. Discoveries at the interface of these disciplines will likely produce solutions to the remaining hurdles, which include more physiological ECM, a hierarchical vascular supply, an adequate and appropriate cell source, and managing the remodeling process for in vivo applications.
